Zentalis Pharmaceuticals, Inc. (ZNTL)
Stock Price:
$29.40 USD
-2.10 (-6.67%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.18B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
40.00M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$29.40 |
| Previous Close |
$31.50 |
| Change ($) |
-2.10 |
| Change (%) |
-6.67% |
| Day's Open |
32.11 |
| Day's Range |
29.40 - 32.87 |
| Day's Volume |
370,254 |
| 52-Week Range |
22.00 - 59.32 |
More Stats
| Market Cap |
1.18B |
| Enterprise Value |
942.48M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
40.00M |
| Float |
30.79M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.43M |
| Short Ratio |
19.18 |
| Short % of Float |
15.25% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.91 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
233.60M |
| Net Cash / Share |
5.84 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$45.00*
(53.06% upside)
Low
43.0
Current: $29.40
High
49.0
Target: 45.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | 0.01 |
| Gross Profit | - | 0.01 |
| Operating Income | -46.85 | -23.78 |
| Net Income | -45.66 | -21.07 |
| Shares Outstanding | 5.60 | 5.59 |
| Earnings Per Share | -8.16 | -3.77 |
| Operating Cash Flow | -39.14 | -24.25 |
| Capital Expenditures | -0.35 | -0.23 |
| Free Cash Flow | -39.50 | -24.48 |
| Cash & Equivalents | 67.49 | 25.15 |
| Net Cash / Debt | 67.49 | 25.15 |
| Assets | 87.48 | 41.00 |
| Liabilities | 19.06 | 8.69 |
| Book Value | -80.11 | 24.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Zentalis Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
75 |
| CEO |
Anthony Y. Sun |
Stock Information
| Ticker Symbol |
ZNTL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ZNTL |
| IPO Date |
April 3, 2020 |
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York. Address: 530 Seventh Avenue, New York, NY, United States, 10018